Project Abstracts - CHIB
Islet on a Chip
Contact PI: Douglas Melton, PhD, Harvard University (UC4 DK104165)
Kit Parker, PhD, co-Investigator, Harvard University
Jeff Karp, PhD, co-Investigator, Brigham and Women’s Hospital
Summary of Project Abstract & Publications
Start Date: September 25, 2014
Mellitus results from failure pancreatic islets leading to an increase in morbidity and mortality. Mechanistic studies of this disease are hindered by low availability, high variability and the cost of human islets. Our recent advances have led to the first successful method to generate mature, glucose sensing- insulin secreting b cells from human pluripotent cells in vitro. This method, and its application using human pluripotent cells, provides a virtually unlimited supply of standardized human β cells. Moreover, as the β cells can be prepared from patient induced pluripotent cells, normal and diseased states can be analyzed. This advance provides a renewable source of b cells for cell replacement therapy for insulin dependent diabetics and the opportunity to perform rigorous disease modeling to identify therapeutic targets for all diabetics. Despite these advances, challenges remain. Robust, sensitive and routine technologies to assess β cell function are lacking. Further, it is unlikely that b cells by themselves will recapitulate the complex biology involved in islet function. As such, the proposed research aims to combine approaches in pluripotent cell and islet biology with tissue engineering to design, build and test new technologies for generating human islets in vitro and assessing their function in microfluidic devices. Using reverse engineering principles we will design and build a bio-inspired microfluidic chip that supports the survival and function of cell clusters containing b cells. This “islet chip” design will enable rigorous and sensitive evaluation of β cell function that goes beyond current technologies. This chip will also provide a platform to evaluate human cadaveric islets by quantifying their functional variability. In parallel, we seek to generate whole islets in vitro using a combination of top-down and bottom-up tissue engineering approaches. Endocrine progenitors from human pluripotent cells will be introduced to a chip designed to screen a combination of substrates, matrixes and mechanical forces to identify a niche that supports differentiation to islet-like structures with all endocrine cell types. The resulting pluripotent cell-derived islets will be evaluated in our islet chip to describe the functional differences between these ES-islets, β cells alone and cadaveric islets. Finally, we will use these technologies for disease modeling and drug screening by generating healthy and diseased islets from induced pluripotent cells representing different disease states (healthy, type 1, type 2 diabetes, MODY) and evaluate the function and response of these islets to diabetes drugs. These studies will provide validated technologies that will increase our understanding of diabetes and speed development of new therapies.